LadRx Planning NDA Submission for Aldoxorubicin & Updates
11 Dec 2024 //
BUSINESSWIRE
XOMA acquires royalty and milestone rights for NPC and pancreatic cancer assets
23 Jun 2023 //
PHARMAFILE
LadRx Announces Reverse Stock Split Effective as of May 17, 2023
18 May 2023 //
BUSINESSWIRE